
Meridian Bioscience VIVO
Quarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Total Assets 2011-2026 | VIVO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 463 M | 450 M | 405 M | 325 M | 251 M | 250 M | 252 M | 183 M | 177 M | 177 M | 161 M | 155 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 463 M | 155 M | 271 M |
Quarterly Total Assets Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 457 M | 463 M | - | 472 M | 459 M | 450 M | 447 M | 450 M | 424 M | 405 M | 405 M | 405 M | 338 M | 325 M | 325 M | 325 M | 250 M | 251 M | 251 M | 251 M | 252 M | 250 M | 250 M | 250 M | 250 M | 252 M | 252 M | 252 M | 186 M | 183 M | 183 M | 183 M | 177 M | 177 M | 177 M | 177 M | 175 M | 177 M | 177 M | 177 M | 157 M | 161 M | 161 M | 161 M | 155 M | 155 M | 155 M | 155 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 472 M | 155 M | 268 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
10.7 B | $ 115.55 | 1.0 % | $ 35.1 B | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
24.7 M | $ 1.67 | -2.34 % | $ 2.22 M | ||
|
CareDx, Inc
CDNA
|
413 M | $ 21.23 | 5.83 % | $ 1.13 B | ||
|
Castle Biosciences
CSTL
|
531 M | $ 24.46 | 3.25 % | $ 679 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 16.31 | 1.75 % | $ 493 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
7.14 B | $ 169.8 | 1.23 % | $ 8.42 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
Illumina
ILMN
|
6.3 B | $ 127.88 | 1.95 % | $ 20.3 B | ||
|
Guardant Health
GH
|
2.01 B | $ 88.91 | 1.18 % | $ 11.1 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
Lantheus Holdings
LNTH
|
2.23 B | $ 84.33 | 1.82 % | $ 5.69 B | ||
|
Interpace Biosciences
IDXG
|
33.8 M | $ 1.98 | -2.37 % | $ 8.76 M | ||
|
Medpace Holdings
MEDP
|
1.98 B | $ 410.54 | 4.35 % | $ 11.8 B | ||
|
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 27.47 | -0.58 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 9.54 | 2.03 % | $ 2.07 B | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.14 | -0.47 % | $ 4.92 M | ||
|
National Research Corporation
NRC
|
135 M | $ 17.23 | -0.12 % | $ 386 M | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 102.17 | -3.92 % | $ 8.43 B | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 263.8 | -0.43 % | $ 21.9 B | ||
|
Celcuity
CELC
|
467 M | $ 121.03 | 6.58 % | $ 5.66 B | ||
|
OpGen
OPGN
|
9.86 M | - | -16.95 % | $ 1.54 M | ||
|
NeoGenomics
NEO
|
1.36 B | $ 8.29 | 4.8 % | $ 1.06 B | ||
|
Myriad Genetics
MYGN
|
707 M | $ 4.78 | -0.21 % | $ 443 M | ||
|
Natera
NTRA
|
1.39 B | $ 203.75 | 1.3 % | $ 20.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 196.27 | -1.66 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | ||
|
PerkinElmer
PKI
|
12.2 B | - | -0.91 % | $ 14.7 B | ||
|
Organovo Holdings
ONVO
|
14.6 M | - | -2.3 % | $ 19.4 M | ||
|
Precipio
PRPO
|
21.3 M | $ 28.0 | 3.57 % | $ 44.9 M | ||
|
Personalis
PSNL
|
270 M | $ 6.1 | 3.39 % | $ 361 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 20.69 | 0.49 % | $ 223 M | ||
|
Pacific Biosciences of California
PACB
|
784 M | $ 1.56 | -0.64 % | $ 468 M |